Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on October 8th and 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of common stock on October 8th and 9th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• On October 8, 2024, Lyssikatos sold 13,167 shares at a weighted average price of $27.9618 and 100 shares at $28.51.
• On October 9, 2024, Lyssikatos sold 34,289 shares at a weighted average price of $28.1199 and 3,589 shares at $28.5199.
• Following these transactions, Lyssikatos indirectly owns 1,016,035 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged 10b5-1 trading plan. It doesn't necessarily reflect a positive or negative view of the company's future prospects.

Industry Context

Insider selling can be interpreted in various ways by the market. While sales under a 10b5-1 plan are pre-arranged and may not necessarily indicate a negative outlook on the company, investors often scrutinize such transactions for potential insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the pre-planned nature of the sales mitigates potential negative interpretations.
• The company's reputation could be affected depending on how the market perceives the insider selling activity.

Key Dates